Qinghai Chenfei Pharmaceutical First Market Approval for Exenatide Biosimilar Supported by UP-Pharma
发布时间 : 2022-08-19
点击 : 0
Qinghai Chenfei Pharmaceutical First Market Approval for Exenatide Biosimilar Supported by UP-Pharma
- Categories:News & Events
- Author:
- Origin:
- Time of issue:2022-08-19 16:35
- Views:
(Summary description)Exenatide biosimilar , Qinghai Chenfei Pharmaceutical , UP-Pharma
Qinghai Chenfei Pharmaceutical First Market Approval for Exenatide Biosimilar Supported by UP-Pharma
(Summary description)Exenatide biosimilar , Qinghai Chenfei Pharmaceutical , UP-Pharma
- Categories:News & Events
- Author:
- Origin:
- Time of issue:2022-08-19 16:35
- Views:
Information
Congratulations to Qinghai Chenfei Pharmaceutical for first market approval of Exenatide biosimilar in China for controlling high blood sugar levels. Utilizing state-of-art analytical platform, UP-Pharma provided highly sensitive and robust LC/MS/MS bioanalytical method to support Exenatide biosimilar clinical development programs and helped to accelerate its market approval in China. Through the fruitful collaboration, the quality work from UPP scientists help our clients to bring better medicine to patients.
Scan the QR code to read on your phone
Previous:
None
Next:
Appreciation Letter
Previous:
None
Next:
Appreciation Letter
Contact Us
Beijing Address：Tower B, No.33 Science Park Road, Changping District, Beijing, P. R. China 102206
Shanghai Address：Building 30, Lane 908, Ziping Road, Pudong New Area, Shanghai, P. R. China 201318
Tianjin Address：Building B03, Venture Headquarters, Fuyuan Road North, Wuqing Development Zone, Tianjin, P. R. China 301700
Guangxi Address：Building 3, Yunlang Science Park, Fangcheng District, Fangchenggang City, Guangxi,P. R. China 838000
Business Email：BD@up-pharma.com
Recruitment Email：hr@up-pharma.com
Copyright © 2022 United-Power Pharma Tech Co., Ltd (UPP) All Rights Reserved 京ICP备15042399号
